A Positive Amphetamine Immunoassay in a Patient on Buprenorphine
Ms. R is a 52-year-old woman with opioid use disorder on buprenorphine/naloxone 12/3 mg daily and fibromyalgia. She takes bupropion XL 300 mg for depression, gabapentin 600 mg three times daily, and occasionally OTC pseudoephedrine for allergies. Her clinic performs random urine immunoassays. One sample is positive for amphetamines; the lab cutoff is 500 ng/mL. She denies any stimulant use since age 20, when she briefly used cocaine. Her PDMP shows only buprenorphine and bupropion. She is tearful and worried about being discharged. The urine creatinine is normal and specific gravity 1.015. She has no tachycardia, mydriasis, or weight loss.
1. How should the positive amphetamine immunoassay be interpreted, and what is the immediate next step?
Read the worked answer
An immunoassay is a screening test, not a diagnosis. Bupropion and its metabolites are a well-recognized cause of false-positive amphetamine immunoassays; pseudoephedrine/ephedrine, labetalol, ranitidine, selegiline, and some antipsychotics can also cross-react. The cutoff and the specific assay matter. The immediate step is to order a definitive method, preferably LC-MS/MS or GC-MS, on the same specimen before making any clinical or administrative decision. Do not discharge her or label her as relapsing based on the screen.
Also review her medication list, including OTC products and supplements, and ask nonjudgmentally about stimulant use, prescription stimulants, and synthetic cathinones. Her normal vital signs and pupils lower but do not eliminate the probability of relapse; stimulant use can be covert. A negative confirmatory test supports a false positive but does not prove abstinence. Document that the screen was presumptive and that confirmation is pending.
2. What clinical and systems factors would guide whether this represents a relapse versus a false positive?
Read the worked answer
Clinical factors include corroborated history, physical signs (tachycardia, hypertension, mydriasis, weight loss, insomnia, nasal lesions), behavior, and whether DSM-5 criteria for stimulant use disorder are met. Ask about prescription stimulants for ADHD, weight-loss products, and decongestants. Check the PDMP for stimulant prescriptions.
Systems factors include a clinic policy that requires confirmation before punitive action, a laboratory medical review process, and clear communication that results are preliminary. A single positive screen has low positive predictive value when prevalence is low. If the LC-MS/MS is negative, cross-reactivity is the likely explanation. If positive, treat it as a clinical event rather than a crime: assess safety, offer treatment, and consider more frequent monitoring. Buprenorphine/naloxone and gabapentin do not typically cross-react with amphetamine immunoassays. Avoid anchoring on her remote history of cocaine use.
3. How would you communicate the outcome to the patient and document it?
Read the worked answer
Tell her promptly that the screening result is not conclusive and that a confirmation test is being sent. Explain false positives in plain language and avoid blaming her. If confirmation is negative, state clearly that the result was a false positive, notify the laboratory and clinic, and document the medications likely responsible. Continue buprenorphine and monitoring; do not impose additional punitive urine tests. If confirmation is positive, present it nonjudgmentally, assess for stimulant use disorder, and discuss treatment options.
Documentation should include the screening assay and cutoff, the confirmatory method and result, medications reviewed, clinical findings, and the shared plan. Use recovery-oriented language. If the clinic has a policy of discharge for positive screens, advocate for revision because immunoassay-only decisions are unsafe. Close the loop with the patient and, if she wishes, her daughter.